NephroGenex is a drug-development company focusing on kidney disease.
The Company is developing Pyridorin™ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.
Pyridorin™ has demonstrated a significant treatment effect in slowing the progression of diabetic nephropathy in two Phase 2 clinical trials, and it has been awarded Fast Track status by the FDA. Pyridorin™ is one of the leading drug candidates in advanced clinical trials for diabetic kidney disease.
NephroGenex has recently initiated a new Phase 2b clinical trial (PYR-210) that is evaluating the safety and efficacy of Pyridorin™ in slowing the progression of nephropathy in patients with type 2 diabetes.
| “Chronic kidney disease (CKD) represents an enormous burden on the health care system of the U.S. with treatment costs exceeding at $24 billion”
(U.S. Renal Data System. USRDS 2005 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive Kidney Disease: Bethesda, MD, 2005)
|
|
